Subscribe free

Cytoreductive Surgery & Peritoneum ·

Preoperative CA 19-9 predicts disease progression in colorectal peritoneal metastases treated with CRS/HIPEC

Elevated levels of CA 19-9, a tumor marker, were found to be associated with decreased progression-free survival (PFS) in patients with colorectal peritoneal metastases (CRPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The study, which included 279 patients, showed that patients with elevated CA 19-9 had a much worse PFS rate compared to those with normal levels. CA 19-9 was independently predictive of worse PFS in patients who underwent upfront CRS/HIPEC. However, further prospective studies are needed to confirm this association.

Journal Article by Fackche NT, Schmocker RK (…) Greer JB et 18 al. in Ann Surg Oncol

© 2024. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →